Drugs / Lomustine
Lomustine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | GLEOSTINE | — | 1976-08-04 | fda.gov ↗ |
Trials 72 · started per year
today
US approved 1976
1
1
3
4
4
3
3
1
4
2
3
1
2
2
2
1
3
4
2
2
5
3
2
2
3
3
1
3
2
19761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05017610 | Oct 2021 → Oct 2022 | gliosarcoma | Emory University | Withdrawn | No outcome recorded |
| Phase 0 | NCT04135807 | Mar 2020 → Jan 2028 expected | anaplastic astrocytoma, anaplastic oligodendroglioma, brain oligodendroglioma, glioblastoma | Oliver Jonas | Recruiting | No outcome recorded |
| Phase 0 | NCT02212574 | Apr 2017 → Nov 2018 | medulloblastoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 110 trials | ||||||
| Phase 1 | NCT07145112 | Oct 2025 → Jul 2027 expected | glioblastoma | University of California, Davis | Recruiting | No outcome recorded |
| Phase 1 | NCT05304663 | Jun 2022 → Dec 2024 | glioblastoma | Philogen S.p.A. | Withdrawn | No outcome recorded |
| Phase 1 | NCT03425292 | Mar 2018 → Sep 2022 | malignant glioma | Saint John's Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT01989052 | May 2014 → Mar 2015 | malignant glioma | Annick Desjardins | Terminated | No outcome recorded |
| Phase 1 | NCT01934361 | Feb 2014 → Jul 2016 | glioblastoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01563614 | Mar 2012 → Nov 2015 | leptomeningeal melanoma | University Hospital, Bonn | Terminated | No outcome recorded |
| Phase 1 | NCT00527657 | Feb 2006 → Feb 2012 | brain neoplasm, melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01682187 | Dec 2005 → May 2012 | glioma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00006024 | Nov 2000 → Jan 2005 | brain glioma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT00005796 | Feb 2000 → Jun 2003 | bone marrow disorder, central nervous system neoplasm, chemotherapy-induced toxicity | Indiana University | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04573192 | Feb 2021 → Mar 2025 | glioblastoma | Philogen S.p.A. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04421378 | Jun 2020 → Jul 2023 | glioblastoma | Karyopharm Therapeutics Inc | Terminated | No outcome recorded |
| Phase 1/2 | NCT02765165 | Apr 2016 → Jul 2020 | glioblastoma | Proximagen Limited | Terminated | No outcome recorded |
| Phase 230 trials | ||||||
| Phase 2 | NCT07632209 | Jun 2026 → Jun 2028 expected | small cell lung carcinoma | Yayi He | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07120984 | Jan 2026 → Jan 2029 expected | glioma | Philogen S.p.A. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06336291 | May 2024 → Jun 2026 overdue | glioblastoma | Philogen S.p.A. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04863950 | May 2022 → Aug 2026 overdue | glioblastoma | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 2 | NCT04049669 | Oct 2019 → Aug 2026 overdue | diffuse intrinsic pontine glioma, ependymoma, glioblastoma, medulloblastoma | Theodore S. Johnson | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03678883 | Jan 2019 → Jun 2026 overdue | T lymphoblastic leukemia/lymphoma, bone cancer, breast neoplasm, colorectal neoplasm +8 | Actuate Therapeutics Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03463265 | Aug 2018 → Aug 2022 | glioblastoma | Aadi Bioscience, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02724579 | Nov 2017 → Mar 2028 expected | medulloblastoma | Children's Oncology Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03022578 | Nov 2017 → Feb 2021 | anaplastic astrocytoma, glioblastoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT02986178 | Jun 2017 → Sep 2022 | malignant glioma | Istari Oncology, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02788201 | Mar 2017 → Oct 2019 | urinary bladder cancer, urothelial carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01775475 | Sep 2016 → Apr 2021 | diffuse large B-cell lymphoma, large-cell immunoblastic lymphoma, precursor lymphoblastic lymphoma/leukemia | AIDS Malignancy Consortium | Completed | No outcome recorded |
| Phase 2 | NCT01562197 | Apr 2014 → Aug 2018 | glioblastoma | Bart Neyns | Completed | No outcome recorded |
| Phase 2 | NCT01737346 | Oct 2012 → Sep 2013 | glioblastoma | Incheon St.Mary's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01582269 | Apr 2012 → Jul 2014 | glioblastoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01067469 | Jan 2010 → Oct 2016 | brain cancer, glioblastoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00989352 | Sep 2009 → Jun 2011 | primary central nervous system lymphoma | University Hospital Freiburg | Unknown | No outcome recorded |
| Phase 2 | NCT00293280 | Jul 2005 → Jul 2007 | lung cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00100802 | Mar 2005 → Sep 2012 | anaplastic astrocytoma, gliosarcoma, spinal cord neoplasm | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00274911 | Feb 2004 → Mar 2010 | central nervous system neoplasm | Children's Cancer and Leukaemia Group | Unknown | No outcome recorded |
| Phase 2 | NCT00072345 | Jul 2003 → Aug 2004 | cutaneous melanoma, ocular melanoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00276666 | Nov 2001 → Mar 2010 | central nervous system neoplasm | Children's Cancer and Leukaemia Group | Unknown | No outcome recorded |
| Phase 2 | NCT00031590 | Apr 2001 → May 2011 | brain cancer, medulloblastoma | Children's Hospital of Philadelphia | Terminated | No outcome recorded |
| Phase 2 | NCT00074191 | Jan → Oct 2000 | lymphoma | OHSU Knight Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00003929 | Jun 1998 → Mar 2000 | lymphoma | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT00049439 | Mar 1998 → Oct 2005 | lymphoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00003101 | Aug 1997 → Jan 2002 | central nervous system neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00003114 | Jul 1997 → Jun 2002 | lymphoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00003113 | Jul 1997 → Dec 2002 | lymphoma | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00002806 | Jul 1996 → Jan 2003 | central nervous system neoplasm | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT02066220 | Jun 2014 → Dec 2026 expected | brain cancer | University Medical Center Hamburg-Eppendorf | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT00003375 | Oct 1998 → Aug 2005 | central nervous system neoplasm | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 319 trials | ||||||
| Phase 3 | NCT07100730 | Nov 2025 → Jul 2027 expected | adult glioblastoma | Telix Pharmaceuticals (Innovations) Pty Limited | Recruiting | No outcome recorded |
| Phase 3 | NCT06419946 | Feb 2025 → Dec 2031 expected | IDH-wildtype glioblastoma | Vastra Gotaland Region | Recruiting | No outcome recorded |
| Phase 3 | NCT05095376 | Mar 2022 → Feb 2026 overdue | gliosarcoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05331521 | Apr 2021 → Mar 2033 expected | oligodendroglioma | University Hospital Heidelberg | Recruiting | No outcome recorded |
| Phase 3 | NCT03632135 | May 2018 → Jun 2022 | glioblastoma | Cordgenics, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01290939 | Oct 2011 → Oct 2015 | cognitive disorder, glioblastoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 3 | NCT01149109 | Oct 2010 → Apr 2017 | glioblastoma | University Hospital, Bonn | Completed | No outcome recorded |
| Phase 3 | NCT00887146 | Sep 2009 → Oct 2029 expected | central nervous system neoplasm | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00777153 | Oct 2008 → Apr 2010 | glioblastoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00590837 | Feb 2008 → Dec 2012 | acute myeloid leukemia | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 3 | NCT00068952 | Aug 2003 → Mar 2006 | glioblastoma | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00053872 | Feb 2003 → ? | central nervous system neoplasm | University of Leicester | Unknown | No outcome recorded |
| Phase 3 | NCT00052455 | Oct 2002 → Sep 2010 | central nervous system cancer | Institute of Cancer Research, United Kingdom | Completed | No outcome recorded |
| Phase 3 | NCT00003603 | Mar 1998 → ? | plasma cell myeloma | Riverside Haematology Group | Unknown | No outcome recorded |
| Phase 3 | NCT00002944 | Apr 1997 → Feb 2006 | brain neoplasm | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00002875 | Dec 1996 → Feb 2006 | brain neoplasm | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00002840 | Aug 1996 → Mar 2002 | central nervous system neoplasm | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 3 | NCT00480064 | Jul 1995 → May 2007 | acute myeloid leukemia | French Innovative Leukemia Organisation | Completed | No outcome recorded |
| Phase 3 | NCT00002569 | Jul 1994 → Feb 2005 | central nervous system neoplasm | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT02551718 | Sep 2015 → Jun 2020 | acute leukemia of ambiguous lineage, acute lymphoblastic leukemia | University of Washington | Completed | No outcome recorded |
| — | NCT02333513 | Feb 2015 → Dec 2017 | malignant glioma | Hebei Yanda Hospital | Unknown | No outcome recorded |
| — | NCT00317408 | Apr 2004 → Feb 2014 | lymphoma | European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma | Unknown | No outcome recorded |
| — | NCT00058370 | Feb 2003 → Jun 2019 | central nervous system neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT00303810 | Jan 2001 → Dec 2013 | central nervous system neoplasm | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
Also used as a comparator or background therapy in 41 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07629089 Background | Jun 2026 → Jun 2030 expected | brain cancer | Megan Mantica | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT00503204 Background | Sep 2007 → Dec 2008 | brain neoplasm, glioblastoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03382977 Comparator | Dec 2017 → Jul 2025 | glioblastoma | VBI Vaccines Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT00948389 Comparator | Oct 2009 → May 2011 | glioblastoma | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT06816134 Comparator | Jan 2025 → Jan 2028 expected | acute lymphoblastic leukemia, acute myeloid leukemia | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 2 | NCT06325683 Comparator | Nov 2024 → Jul 2028 | glioblastoma | National Cancer Institute (NCI) | Suspended | No outcome recorded |
| Phase 2 | NCT06177964 Comparator | Jul 2024 → Feb 2029 expected | glioblastoma | Darell Bigner | Recruiting | No outcome recorded |
| Phase 2 | NCT04402073 Background | Nov 2022 → Jun 2025 | medulloblastoma | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded |
| Phase 2 | NCT04933942 Background | Sep → Dec 2022 | high grade astrocytic tumor | European Organisation for Research and Treatment of Cancer - EORTC | Withdrawn | No outcome recorded |
| Phase 2 | NCT04762069 Comparator | May 2021 → Apr 2026 overdue | adult glioblastoma | CNS Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02926222 Comparator | Nov 2015 → Jul 2017 | glioblastoma | Veneto Institute of Oncology IRCCS | Completed | No outcome recorded |
| Phase 2 | NCT02343406 Comparator | Feb 2015 → Jun 2019 | glioblastoma | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01860638 Background | Aug 2013 → Jan 2017 | glioblastoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT05898451 Background | Jun 2009 → Nov 2011 | cancer | Refnot-Pharm Ltd | Completed | No outcome recorded |
| Phase 2 | NCT00504660 Comparator | Sep 2003 → Aug 2010 | brain cancer, glioblastoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00431561 Comparator | Apr 2003 → Mar 2009 | anaplastic astrocytoma, glioblastoma | Isarna Therapeutics GmbH | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT03970447 Comparator | Jul 2019 → Jun 2028 expected | glioblastoma | Global Coalition for Adaptive Research | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03758014 Comparator | Nov 2018 → Oct 2020 | glioblastoma | Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd | Unknown | No outcome recorded |
| Phase 2/3 | NCT03025893 Comparator | Aug 2018 → Jan 2022 | adult glioblastoma, brain glioma | Amsterdam UMC, location VUmc | Unknown | No outcome recorded |
| Phase 2/3 | NCT02678975 Background | Jan 2017 → Jan 2021 | glioblastoma | Sahlgrenska University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02414165 Comparator | Nov 2015 → May 2019 | anaplastic astrocytoma, glioblastoma | Tocagen Inc. | Terminated | No outcome recorded |
| Phase 316 trials | ||||||
| Phase 3 | NCT05904119 Background | Mar 2024 → Sep 2027 expected | glioblastoma | European Organisation for Research and Treatment of Cancer - EORTC | Recruiting | No outcome recorded |
| Phase 3 | NCT05902169 Comparator | Jan 2024 → Jan 2028 expected | glioblastoma | CarThera | Recruiting | No outcome recorded |
| Phase 3 | NCT05382338 Background | Feb 2023 → Dec 2029 expected | childhood medulloblastoma | Children's Oncology Group | Recruiting | No outcome recorded |
| Phase 3 | NCT05326464 Background | Oct 2022 → Feb 2025 | glioblastoma | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT04702581 Background | Dec 2021 → Dec 2030 expected | oligodendroglioma | Hospices Civils de Lyon | Recruiting | No outcome recorded |
| Phase 3 | NCT03149575 Comparator | Oct 2017 → May 2019 | brain cancer, glioblastoma | DelMar Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02796261 Comparator | Jul 2016 → Jun 2023 | anaplastic astrocytoma | Orbus Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT02444000 Background | Sep 2015 → Oct 2022 | malignant glioma | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT00761280 Comparator | Dec 2008 → Feb 2012 | anaplastic astrocytoma, glioblastoma | Isarna Therapeutics GmbH | Terminated | No outcome recorded |
| Phase 3 | NCT00295815 Comparator | Jan 2006 → Aug 2007 | glioblastoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00085735 Background | Apr 2004 → Mar 2016 | medulloblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00278278 Background | Sep 2003 → Mar 2010 | central nervous system neoplasm | German Society for Pediatric Oncology and Hematology GPOH gGmbH | Unknown | No outcome recorded |
| Phase 3 | NCT00700544 Background | Jun 2002 → Apr 2005 | acute myeloid leukemia | University Hospital, Grenoble | Completed | No outcome recorded |
| Phase 3 | NCT00004259 Comparator | Jun 2000 → Feb 2015 | central nervous system neoplasm | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00003788 Background | Apr 1998 → ? | central nervous system cancer | Colorado Health Foundation | Unknown | No outcome recorded |
| Phase 3 | NCT00925873 Comparator | Jun 1996 → Apr 2000 | acute myeloid leukemia | French Innovative Leukemia Organisation | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05518383 Background | May 2022 → May 2025 overdue | Burkitt lymphoma, primary central nervous system lymphoma, primary mediastinal large B-cell lymphoma | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Recruiting | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT05410301 Background | Apr 2023 → Aug 2026 | glioblastoma | Varun Monga, MD | Withdrawn | No outcome recorded |
| — | NCT05667402 Comparator | Jan 2023 → Dec 2025 | central nervous system leukemia, disease related to hematopoietic stem cell transplant | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| — | NCT02076152 Background | Feb 2014 → Apr 2019 | glioblastoma | Massachusetts General Hospital | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 118 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lomustine | “The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs (Temozolomide, Lomustine, Irinotecan, Carboplatin,...” NCT04135807 ↗100“Cumulative doses of chemotherapy drugs: cisplatin 210 mg/m2, lomustine (CCNU) 225 mg/m2, vincristine 18 mg/m2, cyclophosphamide 6 g/m2.” NCT02066220 ↗ “Induction therapy included idarubicin 8 mg/m2 on days 1 to 5, cytarabine 100 mg/m2 on days 1 to 7, and lomustine 200 mg/m2 on day 1.” PMID 28129526 ↗ Oct 2016 “Regimen A: Patients receive oral lomustine and cisplatin on day 0 and vincristine on days 0, 7, and 14” NCT00031590 ↗ “Day 1: Lomustine (CCNU) at 110 mg/m2 body surface orally,” NCT05331521 ↗ “lomustine (CCNU), PCV or temozolomide” NCT02678975 ↗ “and Dacarbazine, Lomustine, Cisplatin” NCT05898451 ↗ “Lapatinib Lomustine Melphalan” NCT02551718 ↗ “Lapatinib, Lomustine, Mechlor” NCT02788201 ↗ |
| Known as | BCNU | “Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin” NCT05518383 ↗ |
| Known as | CCNU | “Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:
* Carboplatin;
* Irinotecan;
* Etoposide;
*...” NCT03632135 ↗25“A Phase 1/2 Dose-escalation of USL311 as Single Agent and in Combination With Lomustine (CCNU) in Subjects With Advanced Solid Tumors, With Subsequent Single Agent and...” NCT02765165 ↗ “mBuCy conditioning regimen（CCNU 250mg/m2/d -9d, Ara-C 2g/m2/d -8d; CDA 5 mg/m2/d -8d; Busulfan 3.2 mg/kg/d from -7 to -5 days; Cyclophosphamide 1.8 mg/m2/d from -4 to -3 days）” NCT06816134 ↗ “The impact of combined procarbazine, CCNU (lomustine), and vincristine (PCV) chemotherapy after radiotherapy (RT) compared with RT alone” PMID 18089866 ↗ Dec 2007 “patients received lomustine (CCNU) plus BEV (CCNU + BEV) or CCNU plus placebo (CCNU + placebo) until further disease progression (PD2).” PMID 30266892 ↗ Sep 2018 “The subjects receive modified BuCY2 conditioning regimen (Busulfan, Cytarabine, ATG, Cyclophosphamide, CCNU) before allo-HSCT.” NCT05667402 ↗ “temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle; PCV (procarbazine, CCNU, vincristine): standard regimen” NCT00431561 ↗ “The product label for lomustine (CeeNu; lomustine; CCNU) provides the following dosing information.” NCT03149575 ↗ “procarbazine, lomustine (CCNU), and vincristine (PCV) is active in patients with recurrent LGO/LGOA” PMID 12525516 ↗ Jan 2003 “Arm A, Cohort 4: nab-sirolimus + lomustine (CCNU) in patients with recurrent high grade glioma” NCT03463265 ↗ “procarbazine, lomustine (also called CCNU), and vincristine” PMID 27050206 ↗ Apr 2016 “Day 1: Lomustine (CCNU) at 110 mg/m2 body surface orally,” NCT05331521 ↗ “reinduction course including CCNU (40 mg orally on day 1)” NCT00925873 ↗ “every-six-week lomustine (CCNU) using a Bayesian model.” NCT01934361 ↗ “lomustine (CCNU), 200 mg/m2 orally at day 1” NCT00590837 ↗ “same drugs plus lomustine (CCNU), 200mg” NCT00480064 ↗ “lomustine (CCNU), PCV or temozolomide” NCT02678975 ↗ “Day 1: CCNU 110 mg/m2 orally;” NCT04702581 ↗ “Day 1: CCNU 110 mg/m2 orally” NCT02444000 ↗ “Drug: Lomustine (CCNU)” NCT04421378 ↗ “Lomustine (CCNU)” NCT00068952 ↗ |
| Known as | CeeNU | “Lomustine (INN), abbreviated as CCNU (original brand name (formerly available) is CeeNU, now marketed as Gleostine), is an alkylating nitrosourea compound used in chemotherapy.” NCT03758014 ↗1“The product label for lomustine (CeeNu; lomustine; CCNU) provides the following dosing information.” NCT03149575 ↗ |
| Known as | Gleostine | “Lomustine (INN), abbreviated as CCNU (original brand name (formerly available) is CeeNU, now marketed as Gleostine), is an alkylating nitrosourea compound used in chemotherapy.” NCT03758014 ↗ |
| Known as | Lomustina | ChEMBL registry synonym — accepted as the source's own label CHEMBL514 ↗ |
| Known as | lomustine (CCNU) | “lomustine (CCNU)” NCT03463265 ↗ |
| Known as | NSC-79037 | ChEMBL registry synonym — accepted as the source's own label CHEMBL514 ↗ |
| Modality | Small molecule | “Lomustine is an approved oral chemotherapy that belongs to the class of drugs called alkylating agents.” NCT00777153 ↗ |
| Route | Oral | “oral lomustine on day 1” NCT00002569 ↗ |